Compare Aurora Cannabis Inc (ACB) vs NetApp Inc. (NTAP) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

NTAP trades at $165.78, up 7.53% in the last session, near its consensus price target of $167.45. The stock shows strong momentum with three consecutive quarterly earnings beats and bullish technical signals from moving averages. Revenue grew to $6.57B in 2025 with an 18.43% net income margin, while cash flow turned positive at $840M. Recent news highlights AI-driven growth opportunities and strategic partnerships enhancing its data infrastructure offerings.

The outlook remains positive given AI demand tailwinds and solid execution, though valuation multiples are elevated. Key risks include competitive pressures and reliance on enterprise spending cycles. Analyst consensus leans neutral with a slight buy bias, suggesting cautious optimism for further upside if growth sustains.